Bristol-Myers Squibb Company

NYSE: BMY
$57.68
-$0.32 (-0.6%)
Closing Price on December 27, 2024

BMY Articles

The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy into the markets and...
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking for.
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
Bristol-Myers Squibb released better-than-expected first-quarter financial results before the markets opened on Thursday.
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes...
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.